Dashboard Tools Market News Investing Ideas Pricing
Search 100,000+ stocks...
English EN
Deutsch DE Español ES
Sign Up
Log in
Novozymes A/S banner

Novozymes A/S
XMUN:NZM2

Watchlist Manager
Novozymes A/S Logo
Novozymes A/S
XMUN:NZM2
Watchlist
Price: 56.92 EUR 0.74% Market Closed
Market Cap: €15.8B
Write Note Create Alert Ask AI

Wall St Price Targets

NZM2 Price Targets Summary
Novozymes A/S

Wall Street analysts forecast NZM2 stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NZM2 is 61.6 EUR with a low forecast of 31.97 EUR and a high forecast of 73.55 EUR.

NZM2 Lowest Forecast
Wall Street Target
€31.97
-44% Downside
NZM2 Average Forecast
Wall Street Target
€61.6
8% Upside
NZM2 Highest Forecast
Wall Street Target
€73.55
29% Upside
Lowest Forecast
Price Target
31.97 EUR
44% Downside
Average Forecast
Price Target
61.6 EUR
8% Upside
Highest Forecast
Price Target
73.55 EUR
29% Upside
Novozymes A/S Competitors:
Price Targets

Revenue
Forecast

3% / Year
Past Growth
-55% / Year
Estimated Growth
Estimates Accuracy
N/A
Average Beat/Miss
3% / Year
Past Growth
-55% / Year
Estimated Growth
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 7 years, the compound annual growth rate for Revenue has been 3%. The projected CAGR for the next 2 years is -55%.

What are analyst estimates?

Gross Profit
Forecast

3% / Year
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
3% / Year
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Gross Profit Forecast
is not available for Novozymes A/S

Operating Income
Forecast

2% / Year
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
2% / Year
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Operating Income Forecast
is not available for Novozymes A/S

Pre-Tax Income
Forecast

0% / Year
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
0% / Year
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Pre-Tax Income Forecast
is not available for Novozymes A/S

Net Income
Forecast

0% / Year
Past Growth
-56% / Year
Estimated Growth
Estimates Accuracy
N/A
Average Beat/Miss
0% / Year
Past Growth
-56% / Year
Estimated Growth
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 7 years, the compound annual growth rate for Net Income has been 0%. The projected CAGR for the next 2 years is -56%.

What are analyst estimates?

Continue NZM2 Research

Summary
NZM2 intrinsic value, competitors valuation, and company profile.
DCF Valuation
NZM2 stock valuation using Discount Cash Flow valuation method.
Relative Valuation
NZM2 stock valuation using valuation multiples.
Wall St Estimates
NZM2 price targets and financial estimates made by Wall Street analysts.
Profitability
Detailed analysis of the company's profitability.
Solvency
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
NZM2 stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financials
Discount Rate
Other Novozymes A/S listings:
OTC • USD
NVZMF
 OTC • USD
NVZMY
 F • EUR
NZM2
 XBER • EUR
NZM2
 LSE • DKK
0Q4U
 F • EUR
NZM
 CSE • DKK
NZYM B
 SWB • EUR
NZM2
 DUS • EUR
NZM2
 CSE • DKK
NSIS B
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is NZM2's stock price target?
Price Target
61.6 EUR

According to Wall Street analysts, the average 1-year price target for NZM2 is 61.6 EUR with a low forecast of 31.97 EUR and a high forecast of 73.55 EUR.

What is the Revenue forecast for Novozymes A/S?
Projected CAGR
-55%

Over the last 7 years, the compound annual growth rate for Revenue has been 3%. The projected CAGR for the next 2 years is -55%.

What is the Net Income forecast for Novozymes A/S?
Projected CAGR
-56%

Over the last 7 years, the compound annual growth rate for Net Income has been 0%. The projected CAGR for the next 2 years is -56%.

Back to Top
ALPHA SPREAD
Follow us
Join 352,100+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Valuation Backtest Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.

AI Assistant
Get AI-powered insights for any company or topic.
Open AI Assistant
Other Tools
Stock Screener
Discover stocks
Stock Comparison
Smarter decisions through side-by-side analysis
Intrinsic Value Calculator
Discover the true worth of your stocks
DCF Value Calculator
Harness the power of DCF

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett